Evidence map›Paper›PMID 21814507›Full record

ArticlePLoS computational biology2011

Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis.

Bálint Mészáros, Judit Tóth, Beáta G Vértessy, Zsuzsanna Dosztányi, István Simon

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. The N-Terminal Extension of theAntibiotics (Basel, Switzerland) · 2025
    Article
  4. MERITS: a web-based integratedBioinformatics advances · 2024
    Article
  5. Article
  6. Potential Efficacy ofMolecules (Basel, Switzerland) · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Bálint MészárosInstitute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary.
Judit Tóth
Beáta G Vértessy
Zsuzsanna Dosztányi
István Simon
Institute of Molecular Life Sciences · HUBudapest University of Technology and Economics · HUHungarian Academy of Sciences · HU

Funding

Mycobacterium tuberculosis dUTPase as a tool in disease controlR01TW008130 · FIC · HUN-REN TERMESZETTUDOMANYI KUTATOKOZPONT · PI TOTH, JUDIT · 2008 to 2012
$252k
FIC NIH HHS 1R01TW008130FIC NIH HHS R01 TW008130
6 · The paper itself

Abstract

Lengthy co-evolution of Homo sapiens and Mycobacterium tuberculosis, the main causative agent of tuberculosis, resulted in a dramatically successful pathogen species that presents considerable challenge for modern medicine. The continuous and ever increasing appearance of multi-drug resistant mycobacteria necessitates the identification of novel drug targets and drugs with new mechanisms of action. However, further insights are needed to establish automated protocols for target selection based on the available complete genome sequences. In the present study, we perform complete proteome level comparisons between M. tuberculosis, mycobacteria, other prokaryotes and available eukaryotes based on protein domains, local sequence similarities and protein disorder. We show that the enrichment of certain domains in the genome can indicate an important function specific to M. tuberculosis. We identified two families, termed pkn and PE/PPE that stand out in this respect. The common property of these two protein families is a complex domain organization that combines species-specific regions, commonly occurring domains and disordered segments. Besides highlighting promising novel drug target candidates in M. tuberculosis, the presented analysis can also be viewed as a general protocol to identify proteins involved in species-specific functions in a given organism. We conclude that target selection protocols should be extended to include proteins with complex domain architectures instead of focusing on sequentially unique and essential proteins only.

Indexed as

Amino Acid SequenceAnti-Bacterial AgentsAntigens, BacterialBacterial ProteinsCluster AnalysisConserved SequenceDrug DesignGenomicsHumansMolecular Targeted TherapyMycobacterium tuberculosisProtein Serine-Threonine KinasesProtein Structure, TertiaryProteomeSequence Analysis, ProteinTuberculosisAnti-Bacterial AgentsAntigens, BacterialBacterial ProteinsProtein Serine-Threonine KinasesProteome

Identifiers

PMID21814507
PMCPMC3140968
OpenAlexW2016185755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.